





12<sup>th</sup> Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice and Post-MASCC

## Liquid biopsy: ready for clinical practice?

Michail Ignatiadis MD, PhD Jules Bordet Institut, Université Libre de Bruxelles









## Imaging and liquid biopsy: complementary tools

## Anatomical & Functional information




## Genomic & Phenotypic information




### **Precicion Medicine**

### Outline



### Outline




### 1st Liquid biopsy test approved



The **cobas**<sup>®</sup> EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined EGFR mutations of in NSCLC patients

Drug	FFPET	Plasma	
TARCEVA® (erlotinib)	Exon 19 deletions and L858R	Exon 19 deletions and L858R	
TAGRISSO <sup>™</sup> (osimertinib)	T790M	T790M	

### ESR1 mutations worse OS (Bolero 2)




ESR1 mutations 33% post 1st line vs 11% starting 1st line

# Fulvestrant better than exemestane in ESR1mut patients (Sofea)

#### PFS in ESR1 mutant

#### PFS in ESR1 wild-type



### Validation is needed!

## Palbo benefit irrespective of baseline ESR1mut status (Paloma 3)

#### PFS in ESR1 mutant


### PFS in *ESR1* wild-type

35

108

(6)

(13)



Fribbens C et al, J Clin Oncol 2016

(3)

(7)

9

16

50

12

0

6

Fulvestrant+Palbociclib

Fulvestrant+Placebo

(95% Cl. 3.5 to 7.4)


Median PFS, 9.5 months

Median PFS, 5.4 months


(95% Cl, 9.2 to not estimable)

# Palbo benefit irrespective of baseline *PIK3CA*mut status (Paloma 3)

#### PFS in PIK3CA mutant




### PFS in PIK3CA wild-type




# Early PIK3CA (clonal) but not ESR1 (subclonal) dynamics predict palbo benefit (Paloma 3)

Circulating DNA ratio D15/D1 (CDR<sub>15</sub>) in patients treated with fulvestrant and palbociclib




O'Leary B, et al, Nat Communications 2018


## Acquired PIK3CA and ESR1 mutations (both arms) whereas acquired RB1 mutations (palbo arm)



## Early versus late resistance and acquired mutations at disease progression




## Benefit from adding everolimus to exemestane depend on ESR1 mut? (Bolero 2)




### Validation is needed!


### Plasma ctDNA: an alternative to metastatic biopsy



### Outline




### **Treat CTC Trial**





### Study flow chart



C					
C		Treatment arm			
			Observation		
		Trastuzumab	arm	Total	
		(N=31)	(N=32)	(N=63)	
		N (%)	N (%)	N (%)	
Age in years					
Median (	(range)	51.4 (31.9 - 69.4)	53.0 (31.4 - 68.6)	52.6 (31.4 - 69.4)	
Pathological tumor s	size in				
mm					
Median (	(range)	25.0 (7.0 - 180.0)	24.0 (4.0 - 840.0)	24.0 (4.0 - 840.0)	
Pathological lymph r	node				
status					
Negative	2	5 (16.1)	6 (18.8)	11 (17.5)	
Positive		26 (83.9)	26 (81.3)	52 (82.5)	
ER status					
Negative	2	9 (29.0)	11 (34.4)	20 (31.7)	
Positive		22 (71.0)	21 (65.6)	43 (68.3)	
Chemotherapy					
Neo-adju	uvant	17 (54.8)	14 (43.8)	31 (49.2)	
Adjuvant	t	14 (45.2)	18 (56.3)	32 (50.8)	
Data are number of patients (%) or median (range).					

T

Ignatiadis M, et al. Ann Oncol 2018


## Efficacy results for primary objective

Fifty-eight patients were evaluable for the primary endpoint, 29 in each arm. In 9 of the 58 patients, CTC(s) were still detected at week 18: 5 in the trastuzumab and 4 in the observation arm (one-sided Fisher exact test, p=0.765).



### **Invasive Disease Free Survival**

Invasive disease free survival





Ignatiadis M, et al. Ann Oncol 2018

#### **B-47: Invasive Disease-Free Survival** % Disease-Free HR 0.98 (95% CI 0.77-1.26) P=0.90 Treatment Ν **Events** 5 year EFS 89.2% ChemoRx ChemoRx+Trast 89.6% No. at Risk ChemoRx **ChemoRx+Trast**


This presentation is the intellectual property of the presenter. Contact them at Lou.Fehrenbacher@kp.org for permission to reprint and/or distribute

### Outline





### ctDNA for early diagnosis



<sup>1</sup> Mutations in cancer genes (e.g. p53 in 10% of non-cancer patients) occur even in individuals who will never develop cancer (Lynnette Fernandez-Cuesta et al EBioMedicine 2016)

### Challenges

• Physicians: Liquid biopsy in breast cancer is there for some time but no clinical utility have been demonstrated'

• Pharma: 'Why use the liquid biopsy approach to give my drug to a small proportion of patients, if I can give it to all comers?'

 Regulators: 'You need a clear pathway for drug approval based on 'liquid biopsy' test'

### **Opportunities**

• Administer the right drug only to those that need it and for as long as they needed (dream of personalized medicine)

• Develop a new model for drug development

### Acknowledgements



Breast International Group







## Women with breast cancer